Publications by authors named "E Melero Calleja"
Background: The efficacy of trifluridine/tipiracil (FTD/TPI) + bevacizumab compared to FTD/TPI for treatment of refractory metastatic colorectal cancer (mCRC) was demonstrated in the SUNLIGHT trial. This analysis of SUNLIGHT investigated the impact of treatment with FTD/TPI + bevacizumab on patient quality of life (QoL) and Eastern Cooperative Oncology Group performance status (ECOG PS).
Methods: Questionnaires (EORTC QLQ-C30 and EQ-5D-5L) and ECOG PS assessments were conducted at baseline and on Day 1 of each treatment cycle.
Article Synopsis
- There is no agreed-upon definition of clinically meaningful outcomes in randomized clinical trials (RCTs) for treating refractory metastatic colorectal cancer (mCRC), despite various recommendations since 2014.
- Many recent RCTs for oncology drug approvals fail to meet the recommended benchmarks set by organizations like ASCO and ESMO, highlighting the need for better standards.
- Quality of life (QoL) is increasingly emphasized alongside efficacy and safety in clinical trials, with the SUNLIGHT trial showing that treatment options like FTD/TPI with bevacizumab can achieve clinically meaningful outcomes while preserving QoL.
Background: To meet the World Health Organization goal of reducing physical inactivity by 15% by 2030, a multisectoral system approach is urgently needed to promote physical activity (PA). We report the process of and findings from a codesigned systems mapping project to present determinants of PA in the context of urban New South Wales, Australia.
Methods: A participatory conceptual mapping workshop was held in May 2023 with 19 participants working in education, transportation, urban planning, community, health, and sport and recreation.
Background: In metastatic colorectal cancer (mCRC), KRAS mutations are often associated with poorer survival; however, the prognostic impact of specific point mutations is unclear. In the phase III SUNLIGHT trial, trifluridine/tipiracil (FTD/TPI) plus bevacizumab significantly improved overall survival (OS) versus FTD/TPI alone. We assessed the impact of KRAS mutational status on OS in SUNLIGHT.
View Article and Find Full Text PDFRhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma. Despite decades of clinical trials, the overall survival rate for patients with relapsed and metastatic disease remains below 30%, underscoring the need for novel treatments. FGFR4, a receptor tyrosine kinase that is overexpressed in RMS and mutationally activated in 10% of cases, is a promising target for treatment.
View Article and Find Full Text PDF